ribavirin has been researched along with Sepsis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acero Fernández, D; Ferri Iglesias, MJ; Figa Francesch, M; Hombrados Verde, M; López Nuñez, C; Louvriex Freire, R; Virolés Torrent, S | 1 |
| Alexander, PC; James, AM; Long, AG; Shiffman, ML | 1 |
| Higaki, K; Ide, T; Karashima, T; Maeyama, Y; Narita, K; Okamura, S; Sakai, T; Sata, M; Sumie, H; Yoshikai, H | 1 |
| Hodson, A; Kasliwal, M; MacMahon, E; Raj, K; Streetly, M | 1 |
| Bolewska, B; Juszczyk, J; Wojtacha, A | 1 |
| Marks, MI | 1 |
6 other study(ies) available for ribavirin and Sepsis
| Article | Year |
|---|---|
[Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Topics: Adult; Aged; Antiviral Agents; Cellulitis; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Parotitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sepsis; Staphylococcal Infections; Treatment Outcome; Withholding Treatment | 2015 |
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate | 2015 |
[Case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during peginterferon/ribavirin combination therapy].
Topics: Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Middle Aged; Neutropenia; Pneumococcal Infections; Pneumococcal Vaccines; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Sepsis; Splenectomy | 2009 |
A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Disease Outbreaks; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Lung Diseases; Male; Middle Aged; Multiple Organ Failure; Parainfluenza Virus 3, Human; Respirovirus Infections; Ribavirin; Sepsis; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 2011 |
[Bacterial endocarditis in the course of sepsis in 7th month of treatment with peginterferon alfa and ribavirin in patient with chronic hepatitis C].
Topics: Antiviral Agents; Endocarditis, Bacterial; Escherichia coli; Escherichia coli Infections; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sepsis; Time Factors; Treatment Outcome | 2007 |
Respiratory syncytial virus infection: the expanded clinical spectrum.
Topics: Humans; Infant; Infant, Newborn; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections; Ribavirin; Sepsis | 1993 |